Trevi Therapeutics Inc Cash Flow-to-Debt Ratio
Trevi Therapeutics Inc cash flow-to-debt ratio. Trevi Therapeutics Inc (TRVI) has a Cash Flow-to-Debt Ratio of -1.93x as of June 2026, meaning its operating cash flow of $-17.43 Million could theoretically repay -2% of its total liabilities ($9.01 Million) in one year. See Trevi Therapeutics Inc (TRVI) financial flexibility to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Trevi Therapeutics Inc (2016–2025)
Cash flow-to-debt ratio of Trevi Therapeutics Inc from 2016 to 2025. Historical debt coverage capacity for Trevi Therapeutics Inc across 10 annual periods. See Trevi Therapeutics Inc balance sheet independence to measure how much of total assets are equity-financed.
Trevi Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
Trevi Therapeutics Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Trevi Therapeutics Inc. For the full cash flow conversion analysis, see Trevi Therapeutics Inc (TRVI) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.13x | $-42.09 Million | $10.20 Million | ▼ -21.5% |
| 2024 | -3.40x | $-38.26 Million | $11.26 Million | ▲ +26.5% |
| 2023 | -4.63x | $-31.71 Million | $6.86 Million | ▼ -155.4% |
| 2022 | -1.81x | $-28.18 Million | $15.56 Million | ▼ -33.9% |
| 2021 | -1.35x | $-28.95 Million | $21.40 Million | ▲ +7.4% |
| 2020 | -1.46x | $-29.00 Million | $19.85 Million | ▲ +65.5% |
| 2019 | -4.23x | $-23.09 Million | $5.46 Million | ▲ +26.4% |
| 2018 | -5.75x | $-18.29 Million | $3.18 Million | ▼ -437.0% |
| 2017 | -1.07x | $-7.97 Million | $7.45 Million | ▼ -146.9% |
| 2016 | -0.43x | $-11.19 Million | $25.82 Million | — |